Last reviewed · How we verify

Labetalol, Nifedipine

Medical College of Wisconsin · Phase 3 active Small molecule

This combination of a non-selective beta-blocker (labetalol) and a calcium channel blocker (nifedipine) reduces blood pressure through dual inhibition of cardiac contractility and vascular smooth muscle contraction.

This combination of a non-selective beta-blocker (labetalol) and a calcium channel blocker (nifedipine) reduces blood pressure through dual inhibition of cardiac contractility and vascular smooth muscle contraction. Used for Hypertension management in pregnancy or hypertensive emergency (Phase 3 context suggests maternal/obstetric indication).

At a glance

Generic nameLabetalol, Nifedipine
Also known asProcardia, Trandate, Normodyne
SponsorMedical College of Wisconsin
Drug classCombination antihypertensive (beta-blocker + calcium channel blocker)
TargetAlpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, L-type calcium channel
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Labetalol blocks alpha-1, beta-1, and beta-2 adrenergic receptors, reducing heart rate and contractility while causing vasodilation. Nifedipine blocks L-type calcium channels in vascular smooth muscle, causing direct vasodilation. Together, they provide complementary antihypertensive effects with potentially synergistic blood pressure reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: